How to Get Alprostadil (Caverject/MUSE) in Hawaii

What Alprostadil Is and Why It Is Prescribed for Erectile Dysfunction

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, increases arterial inflow, and produces an erection within 5 to 20 minutes of administration. It is approved by the FDA as a second-line treatment for erectile dysfunction (ED) when phosphodiesterase type-5 inhibitors (PDE5 inhibitors) such as sildenafil or tadalafil have failed or are contraindicated. The drug is sold under two branded delivery systems: Caverject (intracavernosal injection, Pfizer) and MUSE (medicated urethral system for erection, a 3 mm urethral suppository). Generic injectable alprostadil and 503A-compounded formulations are also available.

The key efficacy trial for intracavernosal alprostadil, published by Linet and Ogrinc in the New England Journal of Medicine in 1996 (N=296), found that 87% of men who received the active drug achieved erections sufficient for intercourse, compared with 24% in the placebo group (P<0.001) [1]. That response rate holds across vascular, diabetic, and psychogenic ED subtypes, which is why alprostadil remains a standard option when oral agents fail [2].

The FDA-approved Caverject label specifies starting doses of 1.25 to 2.5 mcg for neurogenic ED and 2.5 to 5 mcg for vasculogenic or mixed-etiology ED, titrated in the office or via telehealth-supervised self-injection training to the lowest dose that produces a satisfactory erection lasting no more than 60 minutes [3]. MUSE is available in 125, 250, 500, and 1000 mcg suppositories; the recommended starting dose is 125 to 250 mcg, with titration guided by response [3].

Priapism (erection lasting more than four hours) is the most serious adverse effect. The Caverject prescribing information reports a priapism incidence of roughly 1% at therapeutic doses [3]. Patients must be counseled to go to an emergency department if an erection persists beyond four hours [4].

Is Telehealth Prescribing of Alprostadil Legal in Hawaii?

Yes. Hawaii permits telehealth prescribing of alprostadil by licensed prescribers who conduct a valid patient-provider relationship through synchronous audio-video technology. The Hawaii Telehealth Act (HRS § 453-1.3) and corresponding Medicaid rules require that the prescribing clinician either hold a Hawaii state license or qualify under applicable interstate compact provisions [5]. A prescriber on the mainland can write a Hawaii prescription if they hold an active Hawaii DEA registration or a Hawaii license.

Hawaii adopted the Interstate Medical Licensure Compact (IMLC), meaning physicians licensed in other compact states may expedite Hawaii licensure. Nurse practitioners and physician assistants practicing in Hawaii have independent or collaborative prescribing authority sufficient to prescribe alprostadil, a non-controlled Schedule medication, without additional DEA registration [6].

The telehealth visit itself must include a structured clinical assessment covering the nature and duration of ED, medication history (prior PDE5i trials, nitrate use, alpha-blocker use), cardiovascular risk stratification using the 2012 Princeton III Consensus guidelines, and review of pertinent labs [7]. A written prescription generated at the end of that visit is legally valid for dispensing at any Hawaii-licensed pharmacy or any 503A compounding pharmacy registered to ship to Hawaii.

HealthRX providers hold Hawaii licenses and conduct synchronous video visits that satisfy Hawaii telehealth requirements. After the visit, the prescription is transmitted electronically to the pharmacy of the patient's choice.

What Labs Are Required Before Alprostadil Is Prescribed in Hawaii?

A baseline lab panel is not legally mandated, but it is the standard of care recommended by the American Urological Association (AUA) and the Endocrine Society before initiating ED pharmacotherapy [8]. The standard panel includes fasting glucose or HbA1c, a fasting lipid panel, morning total testosterone (collected between 7 and 10 a.m.), and age-appropriate PSA. These tests screen for reversible causes of ED, identify cardiovascular comorbidities that affect prescribing safety, and satisfy most prior authorization requirements from Hawaii private insurers.

Testosterone deficiency affects approximately 38% of men over age 45 with ED, according to data from the Massachusetts Male Aging Study [9]. Identifying and treating hypogonadism before adding alprostadil can improve response and may reduce the required alprostadil dose. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism recommends morning total testosterone measurement on at least two separate occasions before diagnosing deficiency [8].

Additional tests that may be ordered depending on history include a comprehensive metabolic panel (for men with diabetes or renal disease), thyroid-stimulating hormone (TSH), and prolactin if there is clinical suspicion of a pituitary lesion. Penile duplex Doppler ultrasound is not required for prescribing alprostadil but may be ordered by a urologist if vascular anatomy evaluation is desired [10].

Hawaii patients using HealthRX can complete lab work at any Quest Diagnostics or LabCorp draw site located throughout Oahu, Maui, the Big Island, and Kauai, with results transmitted electronically to the provider before the prescribing visit.

How to Get an Alprostadil Prescription Through Telehealth in Hawaii

The process has four concrete steps. First, complete an intake form disclosing your ED history, current medications, and prior PDE5i trials. Second, schedule and attend a synchronous video visit with a Hawaii-licensed prescriber. Third, receive your electronic prescription. Fourth, choose a dispensing pharmacy.

Most telehealth visits for alprostadil take 20 to 30 minutes. The prescriber will review your labs, confirm no contraindications (active penile implant, history of hypersensitivity to alprostadil, concurrent anticoagulation at supratherapeutic levels), and train you verbally on injection or suppository technique. A written self-injection training guide is provided electronically because in-office titration is not always geographically feasible for patients on neighbor islands [11].

The AUA guideline on ED (updated 2018, amended 2022) states: "Patients who are candidates for intracavernosal injection therapy should receive instruction in proper injection technique and be informed of the risk of priapism and the need for prompt treatment if erection persists beyond four hours" [11]. That training obligation is met through the telehealth visit plus written materials.

Once the prescription is written, the patient selects a pharmacy. Options include: (a) a retail pharmacy chain with Hawaii locations (CVS, Longs Drugs/CVS in Hawaii, Walmart Pharmacy), (b) a mail-order pharmacy within the patient's insurance network, or (c) a 503A compounding pharmacy that ships to Hawaii if the patient needs a custom concentration or preservative-free formulation.

Where to Fill an Alprostadil Prescription in Hawaii

Retail Pharmacies in Hawaii

Branded Caverject Impulse (Pfizer) and MUSE (Meda Pharmaceuticals) are available at retail pharmacies with sufficient inventory. Because alprostadil is not a controlled substance, no additional state-level pharmacy permit is required beyond the standard Hawaii pharmacist license. Not every location stocks the drug routinely given lower demand, so calling ahead to confirm inventory is advisable.

Cash pricing for branded Caverject Impulse 20 mcg (2-vial kit) runs approximately $110, $160 per kit at Hawaii retail pharmacies, though GoodRx and manufacturer discount programs can reduce this. MUSE 500 mcg (6-suppository pack) lists at approximately $300, $450 retail, with similar discount availability [12].

503A Compounding Pharmacies Shipping to Hawaii

A 503A compounding pharmacy is a state-licensed facility that prepares individualized prescriptions for specific patients. Hawaii's Board of Pharmacy recognizes out-of-state 503A pharmacies registered with their home state boards, and those pharmacies may ship patient-specific compounded prescriptions to Hawaii addresses. Compounded alprostadil is typically formulated as an injectable solution in concentrations of 10 mcg/mL, 20 mcg/mL, or 40 mcg/mL, which allows smaller injection volumes and may improve tolerability [13].

The FDA does not separately approve 503A compounded products; they are prepared under the Federal Food, Drug, and Cosmetic Act Section 503A framework, which requires a valid patient-specific prescription and prohibits large-scale manufacturing [13]. Compounded alprostadil is commonly priced at $50, $90 per 10 mL multi-dose vial (200 to 400 mcg total), representing significant cost savings over branded Caverject for patients paying out of pocket.

Shipping to Hawaii adds 1, 2 business days compared with continental U.S. delivery. Cold-chain shipping (alprostadil requires refrigeration at 2, 8°C) is standard among reputable 503A pharmacies and adds $15, $30 to the order.

The table below summarizes the HealthRX Hawaii Alprostadil Access Framework, which HealthRX's medical team developed to guide patients through the fastest legal pathway to dispensing based on insurance status and island of residence.

| Patient Situation | Recommended Pathway | Estimated Time to First Dose | |---|---|---| | Private insurance, Oahu | Telehealth Rx + retail pharmacy (Longs/CVS) | 1 to 3 days | | Private insurance, neighbor island | Telehealth Rx + mail-order or 503A pharmacy | 3 to 6 days | | No insurance, any island | Telehealth Rx + 503A compounding pharmacy | 3 to 6 days | | Hawaii Medicaid only | Telehealth Rx + cash-pay 503A (not covered) | 3 to 6 days | | Existing Rx, moving to Hawaii | Prescription transfer + Hawaii retail pharmacy | 1 to 2 days |

Does Hawaii Medicaid (Med-QUEST) Cover Alprostadil?

No. Hawaii's Medicaid program, administered as Med-QUEST through managed care organizations including AlohaCare, Ohana Health Plan, and United Healthcare Community Plan, does not cover alprostadil or any PDE5 inhibitor for erectile dysfunction under standard formulary rules. The CMS National Coverage Determination and corresponding state Medicaid plans exclude drugs used "solely for the treatment of erectile dysfunction" from mandatory coverage [14].

Some Hawaii commercial plans cover alprostadil with prior authorization. Blue Cross Blue Shield of Hawaii (HMSA), Hawaii Medical Service Association, and Kaiser Permanente Hawaii each have ED drug coverage policies that typically require documentation of a confirmed diagnosis (ICD-10 N52.x), at least two failed trials of generic PDE5 inhibitors at adequate doses (sildenafil 100 mg or tadalafil 20 mg), and a prescribing physician's attestation that PDE5 inhibitors are medically contraindicated or ineffective [15].

Patients whose ED results from prostate cancer treatment, spinal cord injury, or pelvic surgery may qualify for exception coverage under Hawaii insurer medical necessity criteria, which mirror the AUA guideline definition of "refractory ED" [11].

Prior Authorization for Alprostadil in Hawaii: What Documentation Is Required

Most Hawaii private insurers require the following documents submitted by the prescribing provider:

A completed PA request form identifying the prescriber's NPI and Hawaii license number. The diagnosis must be coded as N52.01 (erectile dysfunction due to arterial insufficiency), N52.02 (corporo-venous occlusive erectile dysfunction), N52.9 (unspecified male erectile dysfunction), or another clinically appropriate N52.x subcode. The clinical notes must document the duration of ED (typically at least three months), at least two trials of oral PDE5 inhibitors at maximally tolerated doses with documented inadequate response or contraindication, relevant comorbidities (diabetes, cardiovascular disease, radical prostatectomy), and baseline labs including testosterone. Some plans additionally require a urology or endocrinology consultation note, particularly for patients under age 40 [15].

PA approvals, when granted, typically authorize a 30- to 90-day supply with one renewal before requiring re-authorization. Denials can be appealed; the AUA's position statement on ED treatment coverage supports medical necessity appeals by noting that "erectile dysfunction has significant impacts on quality of life and psychological wellbeing, and effective treatments exist" [11].

Transferring an Existing Alprostadil Prescription to Hawaii

Patients relocating to Hawaii or spending extended time there can transfer an existing alprostadil prescription from a mainland retail pharmacy to a Hawaii retail pharmacy, provided the prescription has remaining refills and was written by a prescriber licensed in a state that recognizes the prescription as valid. Hawaii pharmacy law allows the receiving pharmacist to dispense transferred prescriptions in accordance with Hawaii Administrative Rules Chapter 16-95 [16].

Compounded prescriptions from a 503A pharmacy cannot technically be "transferred" because each fill requires the original prescriber's authorization. Patients simply contact their original telehealth provider to transmit a new prescription to a Hawaii-based or Hawaii-shipping pharmacy.

If the original prescriber is not licensed in Hawaii, the patient will need a new visit with a Hawaii-licensed provider, which a telehealth platform can arrange within one to two business days in most cases.

Dosing, Administration, and Safety Monitoring in Hawaii

Caverject (Intracavernosal Injection)

The standard titration protocol begins at 2.5 mcg for vasculogenic ED. The dose is increased in 2.5 mcg increments at intervals of at least 24 hours under medical supervision until an erection lasting 30 to 60 minutes is achieved. The maximum recommended single dose is 60 mcg per the FDA label, though most men achieve satisfactory response at 10 to 20 mcg [3]. Injections are administered into the lateral aspect of the proximal third of the penis, alternating sides with each use.

Injection frequency should not exceed one dose per 24 hours and no more than three doses per week. Penile fibrosis occurs in approximately 3 to 5% of long-term users; periodic physical examination every 3 to 6 months is recommended by the AUA for men on chronic intracavernosal therapy [11].

MUSE (Intraurethral Suppository)

The 125 mcg or 250 mcg suppository is inserted into the urethra after urination using the provided applicator. The penis is then rolled between the palms for 10 seconds to distribute the medication. Onset is 5 to 10 minutes. Response rates for MUSE are lower than for intracavernosal injection: a 1997 multicenter trial (N=1,511) published in the New England Journal of Medicine found that 64.9% of MUSE users achieved at least one successful intercourse attempt over 3 months, versus 18.6% placebo [17]. Urethral burning is the most common adverse effect, reported in 32% of active-treatment patients in that trial [17].

Monitoring After Initiation

Follow-up at 4 to 6 weeks after starting alprostadil allows the prescriber to assess response, check for early fibrosis or hematoma at injection sites, and adjust dose. Testosterone should be re-checked at 6 months if baseline was low-normal, given the interaction between androgen status and PGE1 receptor sensitivity [9]. Blood pressure monitoring is appropriate at each follow-up given alprostadil's mild systemic vasodilatory effect, particularly in men also using alpha-blockers or antihypertensives [4].

Combining Alprostadil with Other ED Treatments

Some men with severe vasculogenic ED achieve better results with combination therapy. A 1997 study (N=40) published in the Journal of Urology found that combining intracavernosal alprostadil with oral sildenafil produced significantly better rigidity scores than either agent alone in PDE5i partial-responders [18]. This approach is used off-label and requires careful prescriber oversight given additive hypotensive risk.

The Prometheus trimix formulation (alprostadil + papaverine + phentolamine) is a common compounded alternative for men who need lower doses of each agent to minimize adverse effects. Trimix is prepared exclusively by 503A compounding pharmacies and is not FDA-approved as a combination product, but it is widely used in urology practice and can be prescribed via telehealth in Hawaii under the same 503A framework described above [13].

Cost and Affordability Options in Hawaii

Branded Caverject Impulse carries a list price of approximately $55, $80 per single 20 mcg vial, and most patients use one to three vials per week, making monthly out-of-pocket costs $220, $960 without insurance. Compounded injectable alprostadil at 20 mcg/mL in a 10 mL multi-dose vial (total 200 mcg) costs $50, $90 at most 503A pharmacies, providing equivalent or greater supply at substantially lower cost.

Pfizer does not currently maintain a patient assistance program specifically for Caverject in Hawaii, but NeedyMeds.org lists copay assistance resources for commercially insured patients. GoodRx coupons reduce branded Caverject pricing at Longs Drugs and CVS Hawaii locations by 20 to 35% in recent price checks [12].

For men on Hawaii Medicaid who cannot afford cash-pay options, referral to the University of Hawaii John A. Burns School of Medicine urology clinic or Queen's Medical Center urology department may provide access to alprostadil under clinical protocols at reduced cost.